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BACKGROUND: The 2018 US cholesterol management guidelines recommend 
additional lipid-lowering therapies for secondary prevention in patients with low-
density lipoprotein cholesterol ≥70 mg/dL or non−high-density lipoprotein cholesterol 
≥100 mg/dL despite maximum tolerated statin therapy. Such patients are considered 
at very high risk (VHR) based on a history of >1 major atherosclerotic cardiovascular 
disease (ASCVD) event or a single ASCVD event and multiple high-risk conditions. 
We investigated the association of US guideline-defined risk categories with the 
occurrence of ischemic events after acute coronary syndrome and reduction of 
those events by alirocumab, a PCSK9 (proprotein convertase subtilisin/kexin type 9) 
inhibitor.
METHODS: In the ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular 
Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab), 
patients with recent acute coronary syndrome and residual dyslipidemia despite 
optimal statin therapy were randomly assigned to alirocumab or placebo. The primary 
trial outcome (major adverse cardiovascular events, ie, coronary heart disease death, 
nonfatal myocardial infarction, ischemic stroke, or hospitalization for unstable 
angina) was examined according to American College of Cardiology/American Heart 
Association risk category.
RESULTS: Of 18 924 participants followed for a median of 2.8 years, 11 935 (63.1%) 
were classified as VHR: 4450 (37.3%) had multiple prior ASCVD events and 7485 
(62.7%) had 1 major ASCVD event and multiple high-risk conditions. Major adverse 
cardiovascular events occurred in 14.4% of placebo-treated patients at VHR versus 
5.6% of those not at VHR. In the VHR category, major adverse cardiovascular events 
occurred in 20.4% with multiple prior ASCVD events versus 10.7% with 1 ASCVD 
event and multiple high-risk conditions. Alirocumab was associated with consistent 
relative risk reductions in both risk categories (hazard ratio=0.84 for VHR; hazard 
ratio=0.86 for not VHR; Pinteraction=0.820) and by stratification within the VHR group 
(hazard ratio=0.86 for multiple prior ASCVD events; hazard ratio=0.82 for 1 major 
ASCVD event and multiple high-risk conditions; Pinteraction=0.672). The absolute risk 
reduction for major adverse cardiovascular events with alirocumab was numerically 
greater (but not statistically different) in the VHR group versus those not at VHR 
(2.1% versus 0.8%; Pinteraction=0.095) and among patients at VHR with multiple prior 
ASCVD events versus a single prior ASCVD event (2.4% versus 1.8%; Pinteraction=0.661).
CONCLUSIONS: The US guideline criteria identify patients with recent acute coronary 
syndrome and dyslipidemia who are at VHR for recurrent ischemic events and who 
may derive a larger absolute benefit from treatment with alirocumab.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique 
identifier: NCT01663402.
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Secondary prevention treatment options for pa-tients with established atherosclerotic cardiovas-cular disease (ASCVD) and elevated serum cho-
lesterol values have evolved beyond statins since the 
publication of the 2013 American College of Cardiol-
ogy (ACC)/American Heart Association (AHA) choles-
terol guidelines.1 In the interim, large cardiovascular 
outcomes trials have evaluated nonstatin medications 
in patients with established ASCVD, including ezeti-
mibe and inhibitors of PCSK9 (proprotein convertase 
subtilisin/kexin type 9).2–4 These trials demonstrated 
further reductions in the occurrence of major adverse 
cardiovascular events (MACE) when these therapies 
were added to statins.2–4 Consequently, an update to 
the ACC/AHA cholesterol guidelines was published in 
2018,5 which specifically recommended shared deci-
sion making by clinicians and patients with established 
ASCVD to decide on the use of these nonstatin medi-
cations, informed by expected future risks of recur-
rent cardiovascular events. The guidelines categorize 
 patients with established ASCVD as very high risk (VHR) 
or not VHR based on the presence of multiple prior AS-
CVD events or a single prior ASCVD event and multiple 
high-risk concomitant clinical conditions.
We evaluated the application of the 2018 ACC/AHA 
cholesterol guideline recommendations for patients 
with established ASCVD using data from the ODYS-
SEY OUTCOMES trial (Evaluation of Cardiovascular 
Outcomes After an Acute Coronary Syndrome During 
Treatment With Alirocumab).4 The trial compared ali-
rocumab, a PCSK9 inhibitor, with placebo in patients 
on optimized statin therapy after a recent acute coro-
nary syndrome (ACS). A high percentage of these pa-
tients had been treated with revascularization for the 
index ACS event, and they were well treated with other 
secondary prevention medications. Specifically, we ana-
lyzed the association of the VHR categorization with 
the occurrence of cardiovascular events and the influ-
ence of this categorization on the treatment effect of 
intensive low-density lipoprotein cholesterol (LDL-C) 
lowering with alirocumab.
METHODS
The data that support the findings of this study are avail-
able from the corresponding author on reasonable request. 
Qualified researchers may also request access to study docu-
ments, including the clinical study report, study protocol with 
amendments, blank case report form, statistical analysis plan, 
and data set specifications.
Study Design and End Points
The design and primary findings from the ODYSSEY 
OUTCOMES trial have been published.4,6 The trial was 
approved in each center by the responsible Institutional 
Review Board or Ethics Committee, and all patients provided 
written informed consent. A total of 18 924 patients ≥40 
years of age with a prior ACS hospitalization within 1 to 12 
months on intensive or maximum tolerated statin therapy 
with residual dyslipidemia (LDL-C ≥70 mg/dL, non−high-
density lipoprotein cholesterol ≥100 mg/dL, or apolipoprotein 
B ≥80 mg/dL) were randomly assigned to blinded treatment 
with alirocumab 75 mg every 2 weeks or placebo and fol-
lowed for a median of 2.8 years. The dose of alirocumab was 
blindly adjusted during follow-up to target an on-treatment 
LDL-C level of 25 to 50 mg/dL.
The primary composite end point was MACE, comprising 
death attributable to coronary heart disease, nonfatal myocar-
dial infarction, fatal and nonfatal ischemic stroke, or unstable 
angina requiring hospitalization.6 All end points were adjudi-
cated by an independent clinical events committee that was 
blinded to treatment assignment.
Risk Categorization According to 
Guideline Recommendations
Patients were categorized as VHR with multiple major ASCVD 
events if they had at least 1 prior ASCVD event before the 
qualifying index ACS, including myocardial infarction, 
Clinical Perspective
What Is New?
• We evaluated the application of the 2018 
American College of Cardiology/American Heart 
Association cholesterol management guideline rec-
ommendations for additional lipid-lowering thera-
pies in patients with established atherosclerotic 
cardiovascular disease and residual dyslipidemia 
despite maximum tolerated statin therapy who 
were enrolled in the ODYSSEY OUTCOMES trial 
(Evaluation of Cardiovascular Outcomes After an 
Acute Coronary Syndrome During Treatment With 
Alirocumab).
• Patients classified as very high risk, either because 
of a history of multiple atherosclerotic cardiovas-
cular disease events or a single atherosclerotic 
cardiovascular disease event (trial-qualifying acute 
coronary syndrome) and multiple high-risk condi-
tions, had more than double the risk of recurrent 
cardiovascular events as patients classified as not 
very high risk.
• The very-high-risk category also had a larger abso-
lute benefit of alirocumab treatment.
What Are the Clinical Implications?
• Application of the new guideline recommendations 
for the risk stratification and use of additional lipid-
lowering therapies in patients with established ath-
erosclerotic cardiovascular disease clearly identifies 
patients at very high risk of recurrent cardiovascu-
lar events after an acute coronary syndrome, and 
who may derive substantial benefit from treatment 
with a proprotein convertase subtilisin/kexin type 
9 inhibitor.
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ischemic stroke, or peripheral artery disease.5 Patients who 
did not have multiple major ASCVD events could also be 
categorized as VHR based on the combination of 1 major 
ASCVD event (the qualifying index ACS for the trial) and at 
least 2 high-risk conditions (age ≥65 years, revascularization 
before the index ACS, diabetes mellitus, history of hyperten-
sion, baseline estimated glomerular filtration rate of 15–59 
mL·min–1·1.73 m–2, current smoking, history of heart failure, 
or LDL-C ≥100 mg/dL despite maximum tolerated statin 
therapy).5 The presence of heterozygous familial hypercholes-
terolemia (another high-risk clinical condition specified in the 
guidelines) was not captured on the trial case report form. 
Analyses were performed by the categorization of VHR versus 
not VHR and then with further stratification of the patients 
at VHR according to the presence of multiple major ASCVD 
events versus 1 major ASCVD event with at least 2 high-risk 
clinical conditions.
Statistical Analysis
Summary statistics, such as mean values and proportions, 
were used to compare the baseline clinical characteristics of 
Table 1. Baseline Clinical Characteristics by Very-High-Risk Categorization and by Substratification of Very-High-Risk Patients
Variable
All Patients Non-VHR VHR*
VHR* (Multiple Prior 
Major ASCVD Events)
VHR* (1 Major Prior 
ASCVD Event + 
Multiple High-Risk 
Conditions)
Placebo 
(n=9462)
Alirocumab 
(n=9462)
Placebo 
(n=3525)
Alirocumab 
(n=3464)
Placebo 
(n=5937)
Alirocumab 
(n=5998)
Placebo 
(n=2241)
Alirocumab 
(n=2209)
Placebo 
(n=3696)
Alirocumab 
(n=3789)
Demographics
  Age, y 58.6±9.4 58.5±9.3 54.7±7.6 54.6±7.5 61.0±9.6 60.8±9.5 60.2±9.5 60.6±9.2 61.4±9.6 60.9±9.6
  Male sex 7090 (74.9) 7072 (74.7) 2876 
(81.6)
2808 (81.1) 4214 (71.0) 4264 (71.1) 1749 
(78.0)
1677 (75.9) 2465 (66.7) 2587 (68.3)
Cardiovascular risk factors
  Smoking status           
   Current 2278 (24.1) 2282 (24.1) 576 (16.3) 548 (15.8) 1702 (28.7) 1734 (28.9) 544 (24.3) 521 (23.6) 1158 (31.3) 1213 (32.0)
   Former or never 7183 (75.9) 7180 (75.9) 2948 (83.6) 2916 (84.2) 4235 (71.3) 4264 (71.1) 1697 (75.7) 1688 (76.4) 2538 (68.7) 2576 (68.0)
  Hypertension 6044 (63.9) 6205 (65.6) 1079 (30.6) 1099 (31.7) 4965 (83.6) 5106 (85.1) 1766 (78.8) 1801 (81.5) 3199 (86.6) 3305 (87.2)
  Diabetes mellitus 2751 (29.1) 2693 (28.5) 255 (7.2) 242 (7.0) 2496 (42.0) 2451 (40.9) 852 (38.0) 776 (35.1) 1644 (44.5) 1675 (44.2)
Prior medical history
  Peripheral artery 
disease
386 (4.1) 373 (3.9) 0 0 386 (6.5) 373 (6.2) 386 (17.2) 373 (16.9) 0 0
   Congestive heart 
failure
1449 (15.3) 1365 (14.4) 79 (2.2) 62 (1.8) 1370 (23.1) 1303 (21.7) 596 (26.6) 545 (24.7) 774 (20.9) 758 (20.0)
  Myocardial 
infarction
1843 (19.5) 1790 (18.9) 0 0 1843 (31.0) 1790 (29.8) 1843 (82.2) 1790 (81.0) 0 0
  PCI 1615 (17.1) 1626 (17.2) 26 (0.7) 20 (0.6) 1589 (26.8) 1606 (26.8) 1262 (56.3) 1244 (56.3) 327 (8.8) 362 (9.6)
  CABG 526 (5.6) 521 (5.5) 4 (0.1) 6 (0.2) 522 (8.8) 515 (8.6) 402 (17.9) 374 (16.9) 120 (3.2) 141 (3.7)
  Ischemic stroke 256 (2.7) 268 (2.8) 0 0 256 (4.3) 268 (4.5) 256 (11.4) 268 (12.1) 0 0
Laboratory values
  eGFR, mL/min 79.8±19.1 79.5±19.4 84.9±16.0 84.5±16.0 76.8±20.2 76.6±20.5 77.2±20.1 76.3±19.8 76.6±20.2 76.7±21.0
  LDL-C, mg/dL 92.3±30.8 92.4±31.1 89.8±28.6 89.8±27.5 93.8±31.9 94.0±32.9 96.1±32.7 98.1±35.6 92.4±31.4 91.5±31.0
  Non–HDL-C, 
mg/dL
122±35.5 122±35.0 118±32.9 118±31.4 125±36.7 125±36.7 128±38.0 130±39.6 123±35.8 122±34.7
  HDL-C, mg/dL 44.2±11.4 44.4±11.3 44.2±11.2 44.6±11.2 44.1±11.5 44.2±11.4 43.6±11.2 44.2±11.4 44.5±11.7 44.3±11.4
  Triglycerides, mg/
dL, median (quartile 
1, quartile 3)
129 
(94.7,183)
129  
(93.8, 181)
121  
(89.4, 172)
122  
(88.5, 169)
135  
(97.0, 188)
135  
(97.0, 188)
136  
(98.0, 193)
136  
(97.3, 189)
133  
(96.5, 186)
133 
 (97.0, 187)
  Apolipoprotein B, 
mg/dL
83.3±21.6 83.0±21.3 80.6±20.1 80.2±19.1 84.9±22.3 84.6±22.3 86.6±22.4 87.6±23.7 83.8±22.1 82.9±21.3
Data presented as n (%) or mean±SD unless otherwise indicated.
ACS indicates acute coronary syndrome; ASCVD, atherosclerotic cardiovascular disease; CABG, coronary artery bypass graft; eGFR, estimated glomerular filtration 
rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PCI, percutaneous coronary intervention; and VHR, very high risk.
*Patients were categorized as very-high-risk with (a) multiple major ASCVD events if they had ≥1 prior ischemic event before the qualifying index ACS event, 
including myocardial infarction, ischemic stroke, or peripheral artery disease; or (b) 1 major ASCVD event (the qualifying index ACS event) and ≥2 high-risk conditions 
(age ≥65 years, revascularization before the index ACS event, diabetes mellitus, history of hypertension, baseline eGFR of 15–59 mL·min–1·1.73 m–2, current smoking, 
history of heart failure, or LDL-C ≥2.6 mmol/L (100 mg/dL) despite maximally tolerated statin therapy and ezetimibe).5
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patients among the categorized subgroups by risk status. The 
background frequencies in incidence rates of MACE and its 
components, also cardiovascular and all-cause death, among 
the categorized subgroups by risk status were compared only 
among patients receiving placebo to limit confounding by ran-
domized treatment. The association of baseline LDL-C values 
and the absolute risk increase in MACE and death among the 
categorized subgroups by risk status was evaluated by using 
generalized linear regression models by treatment groups sep-
arately. Kaplan-Meier curves for survival probability over time 
were plotted by treatment groups and by risk status. Both 
relative risk reductions (RRRs) and absolute risk reductions 
(ARRs) by treatment assignment were calculated to evaluate 
the alirocumab treatment effect by subgroup interaction. The 
estimates and tests for hazard ratios (HRs) between treatment 
groups and treatment by risk status interaction used propor-
tional hazard models for RRRs and the Gail-Simon method for 
ARRs.7 Marginal Cox regression models were used to estimate 
treatment HRs and testing of treatment by risk status inter-
action for total (ie, first and potentially subsequent) nonfa-
tal MACE and all-cause death events. Nonparametric mean 
cumulative function curves were created for total events, 
representing the expected (ie, mean) cumulative number of 
events per 100 patients at a given point in time after random-
ization. The SAS 9.4 analytic software package was used to 
perform the statistical analyses.
Table 2. Frequency of Ischemic Events Among Placebo-Treated Patients by Very-High-Risk Categorization and by Substratification of Very-High-
Risk Patients
End Point All Patients Non-VHR VHR
VHR* (Multiple 
Prior Major ASCVD 
Events)
VHR* (1 Major Prior 
ASCVD Event + 
Multiple High-Risk 
Conditions)
MACE
  Events 1052 198 854 458 396
  Patient-years 25 271 9699 15 571 5720 9851
  Incidence rate, /100 patient-years 4.16 2.04 5.48 8.01 4.02
Myocardial infarction
  Events 756 150 606 349 257
  Patient-years 25 530 9754 15 776 5820 9955
  Incidence rate, /100 patient-years 2.96 1.54 3.84 6.00 2.58
Stroke
  Events 152 13 139 68 71
  Patient-years 26 501 9974 16 526 6250 10 277
  Incidence rate, /100 patient-years 0.57 0.13 0.84 1.09 0.69
CHD death
  Events 222 31 191 105 86
  Patient-years 26 915 10 074 16 842 6396 10 446
  Incidence rate, /100 patient-years 0.82 0.31 1.13 1.64 0.82
Unstable angina requiring hospitalization
  Events 60 15 45 25 20
  Patient-years 26 601 9969 16 632 6302 10 330
  Incidence rate, /100 patient-years 0.23 0.15 0.27 0.40 0.19
Cardiovascular death
  Events 271 33 238 127 111
  Patient-years 26 915 10 074 16 842 6396 10 446
  Incidence rate, /100 patient-years 1.01 0.33 1.41 1.99 1.06
All-cause death
  Events 392 56 336 169 167
  Patient-years 26 915 10 074 16 842 6396 10 446
  Incidence rate, /100 patient-years 1.46 0.56 2.00 2.64 1.60
ACS indicates acute coronary syndrome; ASCVD, atherosclerotic cardiovascular disease; CHD, coronary heart disease; eGFR, estimated glomerular filtration rate; 
LDL-C, low-density lipoprotein cholesterol; MACE, major adverse cardiovascular event; and VHR, very high risk.
*Patients were categorized as very high risk with (a) multiple major ASCVD events if they had ≥1 prior ischemic event before the qualifying index ACS event, 
including myocardial infarction, ischemic stroke, or peripheral artery disease; or (b) 1 major ASCVD event (the qualifying index ACS event) and ≥2 high-risk conditions 
(age ≥65 years, revascularization before the index ACS event, diabetes mellitus, history of hypertension, baseline eGFR of 15–59 mL·min–1·1.73 m–2, current smoking, 
history of heart failure, or LDL-C ≥2.6 mmol/L (100 mg/dL) despite maximally tolerated statin therapy and ezetimibe).5
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RESULTS
A total of 18 924 patients were randomly assigned at 
1315 sites in 57 countries, with 9462 patients randomly 
assigned to alirocumab and 9462 patients to placebo. 
Median (quartile 1, quartile 3) follow-up was 2.8 (2.3, 
3.4) years. Among the overall population, 11 935 pa-
tients (63.1%) were categorized as VHR, with 4450 of 
these (37.3%) having multiple major ASCVD events 
and 7485 (62.7%) having 1 major ASCVD event (index 
ACS event) and at least 2 high-risk clinical conditions. 
Among the 7485 patients classified as at VHR because 
of 1 major ASCVD event and at least 2 high-risk clini-
cal conditions, 2568 (41.2%) qualified because of the 
presence of age ≥65 years and hypertension, 1045 
(14.0%) qualified because of age ≥65 years and diabe-
tes mellitus, and 403 (5.4%) qualified because of age 
≥65 years and current smoking (the 3 qualification cat-
egories may not be mutually exclusive). In comparison 
with patients categorized as not VHR, patients at VHR 
were older, more commonly female, and more likely to 
have cardiovascular risk factors and prior cardiovascular 
events and procedures, and, in general, they had higher 
baseline lipid values (Table  1). Comparing patients in 
the VHR group with multiple major ASCVD events to 
those with a single ASCVD event and multiple risk fac-
tors, the former were more frequently male and had 
fewer cardiovascular risk factors.
Among patients in the placebo group, the rates of all 
events were substantially higher in the patients at VHR 
than in those categorized as not VHR (Table 2). When 
placebo-treated, patients at VHR were further strati-
fied by the presence of multiple major ASCVD events 
or 1 major ASCVD event and multiple risk factors; the 
frequencies of ischemic end points were higher among 
those with multiple major ASCVD events.
Treatment with alirocumab was associated with simi-
lar reductions in LDL-C levels among patients catego-
rized as VHR or not VHR (Figure 1A), and also among 
the patients at VHR further stratified by the presence of 
multiple major ASCVD events or 1 major ASCVD event 
and multiple risk factors (Figure 1B).
The Kaplan-Meier curves depicting the longitudinal 
occurrence of MACE events over time demonstrate a 
substantially higher risk of events among those catego-
rized as VHR in comparison with those categorized as 
not VHR, with an earlier and more sustained separation 
of the event curves by alirocumab versus placebo treat-
ment among the patients at VHR (Figure 2A). Similarly, 
the risk of death was greater among patients catego-
rized as VHR, with a separation of the event curves by 
alirocumab versus placebo treatment observed only in 
the VHR group (Figure 2B).
The HR for MACE observed with alirocumab treat-
ment was similar in the VHR (HR, 0.84; 95% CI, 0.76–
0.93) and not VHR (HR, 0.86; 95% CI, 0.70–1.06; 
Pinteraction=0.820) categories and was also similar among 
the patients at VHR further stratified by the presence 
of multiple major ASCVD events (HR, 0.86; 95% CI, 
0.75–0.98) or 1 major ASCVD event and multiple risk 
factors (HR, 0.82; 95% CI, 0.71–0.95; Pinteraction=0.672) 
(Figure 3A). A greater ARR in MACE was observed with 
alirocumab among those categorized as VHR (ARR, 
2.13%; 95% CI, 0.91–3.35) versus those not at VHR 
(ARR, 0.77%; 95% CI, –0.28 to 1.81), but it was not 
statistically different (Pinteraction=0.095). The ARR for ali-
rocumab treatment was similar among the patients at 
VHR with multiple major ASCVD events (ARR, 2.42%; 
95% CI, 0.11–4.73) or with 1 major ASCVD event and 
multiple risk factors (ARR, 1.82%; 95% CI, 0.47–3.17; 
Pinteraction=0.661) (Figure 3A). Similar findings were ob-
served with alirocumab treatment for all-cause death 
(Figure 3B).
An exploratory analysis that stratified patients as 
VHR by the presence of baseline (prerandomization) 
LDL-C levels ≥100 mg/dL demonstrated higher MACE 
and death rates among those with baseline LDL-C 
levels above this threshold and significantly greater 
RRRs and ARRs for both MACE and all-cause death 
with alirocumab treatment (Figure 3A and 3B). Non-
significant but numerically greater RRR and ARR re-
sults were observed with alirocumab treatment in the 
patients not at VHR among those with baseline LDL-C 
levels ≥100 mg/dL.
The treatment effect of alirocumab according to risk 
status was further investigated by total nonfatal MACE 
events and all-cause death (Figure  4A). The RRR was 
identical irrespective of risk status (HRs 0.84 for both 
VHR and not VHR; Pinteraction=0.98). However, the ac-
crual of events was markedly higher among patients 
classified as VHR, with greater ARR by alirocumab, with 
nearly 5 events avoided over 4 years per 100 patients 
in the VHR subgroup in comparison with 1.6 events 
avoided over 4 years per 100 patients in the not VHR 
patient subgroup (Figure 4B).
DISCUSSION
Approximately two-thirds of patients with recent ACS 
and residual dyslipidemia despite optimal statin therapy 
who were enrolled in a contemporary cardiovascular 
outcomes trial were categorized as VHR for future AS-
CVD events based on recently published updates to the 
ACC/AHA cholesterol treatment guidelines.5 The guide-
line-defined risk categories correlated well with the ob-
served risk in this post-ACS population. Moreover, we 
observed that in the VHR category, patients with mul-
tiple major ASCVD events had an even greater risk of 
MACE and all-cause death during longitudinal follow-
up than patients who had only 1 prior major ASCVD 
event (the qualifying index ACS event) with at least 2 
high-risk clinical conditions. Although alirocumab was 
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associated with consistent LDL-C lowering and rela-
tive reductions in the risk of MACE and all-cause death 
across guideline-defined risk categories, we observed a 
numerically greater, but not statistically different, ARR 
for time to first event with alirocumab in patients cat-
egorized as VHR in comparison with those categorized 
as not at VHR. These findings were further informed 
by a total events analysis that demonstrated a larger 
A
B
Figure 1. Impact of alirocumab treatment on temporal changes in achieved LDL-C values. 
Very high-risk categorization (A) and substratification of very high-risk patients (B). ASCVD indicates major atherosclerotic cardiovascular disease; LDL-C, low-
density lipoprotein cholesterol; RF, risk factor; and VHR, very high risk.
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number of events avoided over 4 years with alirocumab 
in the VHR versus not VHR subgroups. Furthermore, 
within the VHR category, we observed similar ARRs for 
time to first event with alirocumab among those who 
had multiple major ASCVD events and those who had 
only 1 prior major ASCVD event and multiple risk fac-
tors. In summary, these findings provide support for 
the application of the updated ACC/AHA cholesterol 
treatment guidelines5 to select the highest-risk patients 
for treatment with additional LDL-C–lowering therapies 
(beyond statins) in the post-ACS setting.
Contemporary trials that evaluated further LDL-C low-
ering with ezetimibe or PCSK9 inhibitors, in addition to 
statin therapy, focused on patients with established AS-
CVD confirmed by a prior ischemic event.2–4 Within this 
context, secondary analyses from these trials have shown 
that multiple high-risk subgroups derive enhanced ben-
efit from additional LDL-C lowering, including those with 
peripheral artery disease, diabetes mellitus, multivessel 
coronary disease with prior coronary artery bypass sur-
gery, and multiple prior myocardial infarction events.8–13 
Our findings provide further confirmation of the incre-
mental benefit of additional LDL-C lowering for patients 
with established ASCVD (leveraging both time to first 
event and total events analyses) using a comprehensive, 
integrated risk-stratification approach recommended by 
recently updated cholesterol guidelines in comparison 
with binary attributions of risk based on the presence or 
absence of a single high-risk clinical characteristic.5 Thus, 
the present data indicate the utility of the ACC/AHA cho-
lesterol treatment guidelines5 risk categories to inform 
decisions on the selection of patients with established 
ASCVD for PCSK9 inhibitor therapy to achieve the great-
est benefits of intensive LDL-C–lowering therapies.
In the post-ACS setting, the risk of recurrent isch-
emic events is greatest in the first 3 to 6 months follow-
ing the index ACS event, so the timing and sequencing 
of additional LDL-C–lowering therapies may need to 
be more front-loaded to have the greatest treatment 
benefit and impact. Treatment with high-intensity statin 
therapy starting at the time of ACS has been shown to 
be superior to placebo and to moderate-intensity statin 
A
B
Figure 2. Occurrence of recurrent ischemic 
events by alirocumab treatment by very-
high-risk categorization and by substratifi-
cation of very-high-risk patients. 
The frequency of MACE (A) and all-cause death 
(B). MACE indicates major adverse cardiovascu-
lar event; and VHR, very high risk.
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therapy for reducing the early risk of recurrent ischemic 
events and correlated with greater relative reductions 
in LDL-C values in the MIRACL trial (Myocardial Isch-
emia Reduction with Aggressive Cholesterol Lowering) 
and PROVE IT–TIMI 22 trial (Pravastatin or Atorvastatin 
Evaluation and Infection Therapy–Thrombolysis in Myo-
cardial Infarction 22), respectively.14,15 Further LDL-C 
 lowering with ezetimibe, added to statin therapy, start-
ed within 10 days of an ACS event, is associated with 
a modest reduction in LDL-C values and recurrent isch-
emic events, but the benefits observed were apparent 
only after 1 year of treatment exposure.2 Similar find-
ings were observed in the ODYSSEY OUTCOMES trial 
with alirocumab, in which treatment was initiated at a 
A
B
Figure 3. Risk reductions associated by treatment, and very-high-risk categorization, substratification of very-high-risk patients, and baseline LDL-C 
for very-high-risk and non–very-high-risk patients. 
MACE (A) and all-cause death (B). An LDL-C value of 100 mg/dL equates to 2.6 mmol/L. ACS indicates acute coronary syndrome; ARR, absolute risk reduction; 
ASCVD, major atherosclerotic cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; MACE, major adverse cardiovascular event; RF, risk factor; RRR, 
relative risk reduction; and VHR, very high risk.
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median of 2.6 months after the index ACS event and a 
separation of event curves became apparent at ≈1 year.4 
In this context, when considering additional LDL-C–
lowering therapies for patients at VHR with ASCVD, 
the 2018 ACC/AHA cholesterol treatment guidelines 
recommend starting with high-intensity statin therapy, 
then adding ezetimibe if LDL-C values remain ≥70 mg/
dL, and finally adding a PCSK9 inhibitor if LDL-C values 
continue to remain ≥70 mg/dL.5 No clinical trial has in-
vestigated such a sequential approach to the addition 
of lipid-lowering therapies to intensive statin treatment. 
Nonetheless, LDL-C reduction with ezetimibe reaches a 
steady state ≈2 weeks after commencing treatment,16 
allowing assessment of the need for further addition 
of a PCSK9 inhibitor within a relatively short period of 
time, perhaps as early as 4 weeks after commencing 
treatment, and in line with the recommended time win-
dow of 4 to 12 weeks for repeat LDL-C measurement in 
the 2018 guidelines.5 In this regard, the new ACC/AHA 
guidelines5 are logical and pragmatic.
The ODYSSEY OUTCOMES trial showed that pa-
tients with ACS and LDL-C ≥100 mg/dL despite high-
intensity statin therapy derived a greater absolute treat-
ment benefit with alirocumab than those with LDL-C in 
the 70 to 100 mg/dL range.4,17 In the present analysis, 
we demonstrate that, among patients with recent ACS 
classified as VHR according to ACC/AHA criteria, the 
benefit of alirocumab treatment was particularly pro-
nounced among those statin-treated patients with LDL-
C ≥100 mg/dL. Therefore, the presence of residual el-
evated LDL-C levels ≥100 mg/dL despite optimal statin 
therapy may be an important criterion to select those 
patients at VHR who will derive substantial benefit from 
the addition of a PCSK9 inhibitor.5,18
Limitations
Limitations of this analysis include insufficient data ele-
ments to identify patients in the ODYSSEY OUTCOMES 
trial with heterozygous familial hypercholesterolemia, 
which is 1 of the designated criteria for VHR. Second, 
the current analysis applies guideline categories only to 
patients with recent ACS, and not to the broader popu-
lation of patients with chronic ASCVD. Third, the analy-
sis of treatment benefit in patients at VHR according to 
baseline LDL-C should be considered in the context of 
trial design. The ODYSSEY OUTCOMES protocol speci-
fied blinded substitution of placebo for alirocumab in 
A
B
Figure 4. Total nonfatal MACE events and death by very high-risk categorization and treatment assignment to 4 years.  
A, Treatment group rates represent the expected number of events per 100 patients for total nonfatal MACE and all-cause death events based on mean cumula-
tive function estimates at 4 years; the total number of events observed are in parentheses. Treatment HRs and associated CIs and high-risk categorization by treat-
ment assignment interaction P value are from marginal Cox regression models. B, Accrual of events per 100 patients. The expected number of nonfatal MACE and 
all-cause death events per 100 patients in the placebo and alirocumab groups at 4 years were 29.9 and 25.1, respectively, for patients classified as very high risk 
and 9.9 and 8.3, respectively, for patients classified as not very high risk. HR indicates hazard ratio; and MACE, major adverse cardiovascular event.
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patients with persistent on-treatment LDL-C levels <15 
mg/dL. As attainment of LDL-C <15 mg/dL on alirocum-
ab was infrequent among patients with baseline LDL-C 
levels >100 mg/dL, that subgroup was more likely to 
have persistent alirocumab treatment than those with 
baseline LDL-C levels <100 mg/dL. Finally, the present 
results should be considered hypothesis-generating be-
cause the analyses were not prespecified, but rather 
were conducted in an ad hoc manner in response to 
publication of the 2018 cholesterol guidelines update5 
in November 2018 (after conclusion of the trial earlier 
in 2018). Future studies may prespecify analyses of data 
according to guideline criteria for risk categories. In ad-
dition, meta-analyses of patient-level data from existing 
PCSK9 inhibitor trials may help to generalize the obser-
vations from the present analysis, which are limited to 
patients with recent ACS.
CONCLUSIONS
New recommendations for the risk stratification of pa-
tients with established ASCVD from the 2018 ACC/
AHA cholesterol guidelines5 for the selection of LDL-C–
lowering therapies appear to identify patients with 
recent ACS and dyslipidemia who are at VHR for re-
current cardiovascular events and who may have an ac-
centuated benefit from alirocumab treatment. Within 
this context, prospective evaluation of decision-support 
tools based on these guidelines will be helpful to deter-
mine the optimal approaches for improving the choles-
terol management of patients in the post-ACS setting.
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